Director Ronen Nehama details initial Nano-X Imaging (NNOX) share and option holdings

Rhea-AI Filing Summary

Nano-X Imaging Ltd. director Ronen Nehama filed an initial ownership report showing his equity position in the company. The filing lists a stock option to buy 50,000 ordinary shares at an exercise price of $17.63 per share, expiring on December 31, 2033, alongside direct holdings of ordinary shares, including shares underlying restricted share units that vest in twelve equal monthly installments from a December 10, 2025 grant.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ronen Nehama

(Last) (First) (Middle)

C/O NANO-X IMAGING LTD., OFER TECH PARK

94 SHLOMO SHMELTZER ROAD

(Street)

PETACH TIKVA 4970602

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	7,792	D
Ordinary shares(1)	17,544	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	(2)	12/31/2033	Ordinary shares	50,000	$17.63	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on December 10, 2025 and that vest in twelve equal monthly installments such that they will be fully vested upon the one-year anniversary of the grant date.

2. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the approval of the grant by the Issuer's Board of Directors (which approval occurred on August 14, 2023), and an additional 6.25% of the options vest on a quarterly basis over the following three years such that all options reported in this row will be fully vested by the four-year anniversary of that grant approval date.

Remarks:

Exhibit 24.1 Power of Attorney

	/s/ Marina Gofman Feler, attorney-in-fact	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Ronen Nehama’s Form 3 for Nano-X Imaging (NNOX) show?

The Form 3 shows director Ronen Nehama’s initial ownership in Nano-X Imaging. It lists direct holdings of ordinary shares and a stock option covering 50,000 ordinary shares, providing a baseline of his equity position when he became a reporting insider.

How many Nano-X Imaging shares are covered by Ronen Nehama’s stock options?

The filing shows a stock option covering 50,000 ordinary shares of Nano-X Imaging. These options have an exercise price of $17.63 per share and an expiration date of December 31, 2033, outlining a long-term equity incentive for the director.

What is the vesting schedule for Ronen Nehama’s Nano-X Imaging stock options?

The options were granted on December 31, 2023 and approved on August 14, 2023. 25% vested after one year from approval, with an additional 6.25% vesting quarterly over three years so all options vest by the four-year anniversary.

What restricted share units (RSUs) does Ronen Nehama hold in Nano-X Imaging?

The filing notes ordinary shares underlying RSUs granted on December 10, 2025. These restricted share units vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the grant date, aligning compensation with continued service over that period.

Does the Form 3 indicate any recent Nano-X Imaging share purchases or sales by Ronen Nehama?

No specific buy or sell transactions are indicated. The Form 3 is an initial ownership report, summarizing Nehama’s existing holdings of Nano-X Imaging ordinary shares and stock options when he became subject to insider reporting requirements.

Why is Ronen Nehama’s Form 3 filing important for Nano-X Imaging (NNOX) investors?

The Form 3 gives investors a transparent view of the director’s equity stake at the start of reporting. It details his direct share holdings, RSUs, and stock options, helping investors understand how his compensation and incentives are tied to Nano-X Imaging’s performance.